RxDoctor Payments Data

Cathy Luo, MD

Interventional Pain Management · Fayetteville, ARNPI 1417964859

Payments from drug & device makers

$2,863in general payments, 2019–2025

Across 184 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$421
  • Lilly USA, LLC$350
  • Collegium Pharmaceutical, Inc.$349
  • Pfizer$316
  • Teva Pharmaceuticals USA, Inc.$216
  • Takeda Pharmaceuticals U.S.A., Inc.$214
  • plus $997 from 18 others

What the payments were for

  • Travel & lodging$201%
  • Food & beverage$2,84399%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few interventional pain management providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$359,961
Medicare patients
187
Services billed
3,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl64$46,623
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,615$41,581
Xtampza ErOxycodone Myristate115$41,415
RelistorMethylnaltrexone Bromide14$31,091
UbrelvyUbrogepant32$28,618
Oxycodone Hcl1,628$25,966
MovantikNaloxegol Oxalate61$24,498
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen889$24,339
Nurtec OdtRimegepant Sulfate18$20,271
OxycontinOxycodone Hcl23$12,144
Oxymorphone Hcl ErOxymorphone Hcl23$10,534
Morphine Sulfate ErMorphine Sulfate576$10,519
Hysingla ErHydrocodone Bitartrate27$9,601
LinzessLinaclotide15$8,190
DayvigoLemborexant21$6,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$349$88,038179 claims
AbbVieUbrelvy, Linzess$170$36,80847 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$421$31,09114 claims
Redhill Biopharma Inc.Movantik$38$24,49861 claims
PfizerNurtec Odt$316$20,27118 claims
Eisai Inc.Dayvigo$58$6,81321 claims
Upsher-smith Laboratories LLCTopiramate$88$30768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain management providers in Arkansason file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →